These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38663455)

  • 1. Interim analysis of the PARADISE study: Benefits of add-on peginterferon-α in NA-treated patients with CHB.
    Jiang S; Guo S; Huang Y; Xu J; Li Y; Zeng Y; Guo Y; Ouyang L; Zhu C; Zhao W; Zhang Q; Guo Q; Xin H; Xie Q
    Antiviral Res; 2024 Jun; 226():105892. PubMed ID: 38663455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-on pegylated interferon augments hepatitis B surface antigen clearance
    Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
    World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk.
    Ren P; Cao Z; Mo R; Liu Y; Chen L; Li Z; Zhou T; Lu J; Liu Y; Guo Q; Chen R; Zhou H; Xiang X; Cai W; Wang H; Bao S; Xu Y; Gui H; Xie Q
    Expert Opin Biol Ther; 2018 Oct; 18(10):1085-1094. PubMed ID: 30182763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis.
    Liu J; Wang T; Zhang W; Cheng Y; He Q; Wang FS
    Hepatol Int; 2020 Dec; 14(6):958-972. PubMed ID: 33185803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Early reduction of serum RANTES can predict HBsAg clearance in patients with chronic hepatitis B treated with nucleos(t)ide analogues combined with peginterferon alpha].
    Jia R; Wang WX; Gao YY; Luan JQ; Qiao F; Liu JY; Yuan JH; Cheng YQ; Wang FS; Fu JL
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):666-672. PubMed ID: 34371537
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B.
    Mao QG; Liang HQ; Yin YL; Tang JM; Yang JE; Wu CC; Chen Y; Zhang MY; Liu YY; Zheng XT; Zhuang LY; Chen SD
    Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101758. PubMed ID: 34303003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation.
    Qi W; Zhang Q; Xu Y; Wang X; Yu F; Zhang Y; Zhao P; Guo H; Zhou C; Wang Z; Sun Y; Liu L; Xuan W; Wang J
    J Viral Hepat; 2020 Apr; 27(4):387-396. PubMed ID: 31755220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological response to combination therapy with nucleos(t)ide analogs and peginterferon alpha in treatment-naïve chronic hepatitis B patients.
    Zhang Q; Li G; Yu Y; Qiu C; Zheng J; Zhang H; Zhang M; Song Z; Yang Y; Du X; Hong J; Lu J; Li N; Tang Q; Xu L; Wang X; Huang Y; Zhang J; Chen Z; Zhang W
    J Viral Hepat; 2019 Jul; 26 Suppl 1():59-68. PubMed ID: 31380588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B.
    Liem KS; van Campenhout MJH; Xie Q; Brouwer WP; Chi H; Qi X; Chen L; Tabak F; Hansen BE; Janssen HLA
    Aliment Pharmacol Ther; 2019 Feb; 49(4):448-456. PubMed ID: 30689258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study.
    Wen C; Wang Y; Tian H; Lei Y; Wang Z; Cai D; Zhou Z; Shi X
    Front Cell Infect Microbiol; 2023; 13():1332232. PubMed ID: 38292859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D.
    Lampertico P; Brunetto MR; Craxì A; Gaeta GB; Rizzetto M; Rozzi A; Colombo M;
    J Viral Hepat; 2019 Jan; 26(1):118-125. PubMed ID: 30187599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
    Boglione L; Cariti G; Di Perri G; D'Avolio A
    J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2.
    Agarwal K; Buti M; van Bömmel F; Lampertico P; Janczewska E; Bourliere M; Vanwolleghem T; Lenz O; Verbinnen T; Kakuda TN; Mayer C; Jezorwski J; Muenz D; Beumont M; Kalmeijer R; Biermer M; Lonjon-Domanec I
    J Hepatol; 2024 Sep; 81(3):404-414. PubMed ID: 38583491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase.
    Zhao Q; Liu K; Zhu X; Yan L; Ding Y; Xu Y; Lou S; Zhao G; Xie Q; Gao Y; Bao S; Wang H
    Antiviral Res; 2020 Dec; 184():104953. PubMed ID: 33065138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study).
    Farag MS; van Campenhout MJH; Sonneveld MJ; Fung S; van Erpecum KJ; Wong DK; Verhey E; de Man R; De Knegt RJ; Brouwer JT; Baak HC; Feld JJ; Liem KS; Boonstra A; Hansen BE; Janssen HLA
    J Viral Hepat; 2024 Apr; 31(4):197-207. PubMed ID: 38243144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pegylated interferon-α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B.
    Ren H; Huang Y
    J Viral Hepat; 2019 Jul; 26 Suppl 1():5-31. PubMed ID: 31380584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis.
    Wei W; Wu Q; Zhou J; Kong Y; You H
    Int J Environ Res Public Health; 2015 Aug; 12(8):10039-55. PubMed ID: 26308024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of the therapeutic efficacy and factors influencing sequential combination of nucleos(t)ide analogues with pegylated interferon alpha for 48~96 weeks in the treatment of patients with chronic hepatitis B].
    Jia R; Wang WX; Zhou ZP; Nie WM; Cheng YQ; Zhao J; Lian F; Luan JQ; Wang FS; Fu JL
    Zhonghua Gan Zang Bing Za Zhi; 2023 Dec; 31(12):1290-1296. PubMed ID: 38253073
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.